

GLENMARK PHARMACEUTICALS LIMITED
STATEMENT OF ASSETS AND LIABILITIES

(` in Millions)

Particulars	STANDALONE		CONSOLIDATED	
	Indian GAAP	Indian GAAP	IFRS	Indian GAAP
	As at	As at	As at	As at
	March 31, 2011	March 31, 2010	March 31, 2011	March 31, 2010
	Audited	Audited	Audited	Audited
SHAREHOLDERS' FUNDS:				
(a) Capital	270.27	269.84	270.27	269.84
(b) Reserves and Surplus	19,527.14	17,428.11	20,102.10	23,017.84
MINORITY INTEREST	-	-	267.01	130.08
FOREIGN CURRENCY MONETARY ITEM TRANSLATION RESERVE	-	36.21	-	264.65
LOAN FUNDS	11,462.46	7,597.55	21,116.45	18,693.91
DEFERRED TAX LIABILITY	330.57	327.71	1,476.30	1,275.01
TOTAL	31,590.44	25,659.42	43,232.13	43,651.33
FIXED ASSETS	2,637.22	2,372.91	22,123.20	23,880.78
INVESTMENTS	10,412.47	9,929.20	181.23	181.23
DEFERRED TAX ASSET	101.27	96.73	2,557.66	564.86
CURRENT ASSETS, LOANS AND ADVANCES				
a) Inventories	1,570.07	1,503.98	8,070.12	7,084.59
(b) Sundry Debtors	1,893.44	3,300.92	11,308.14	10,782.78
(c) Cash and Bank balances	309.49	50.77	1,986.26	1,070.20
(d) Loans and Advances	16,919.38	10,511.14	4,751.16	5,273.10
LESS: CURRENT LIABILITIES AND PROVISIONS				
(a) Liabilities	2,054.90	1,910.41	7,560.38	4,986.47
(b) Provisions	198.00	195.82	185.26	199.74
NET CURRENT ASSETS	18,439.48	13,260.58	18,370.04	19,024.46
TOTAL	31,590.44	25,659.42	43,232.13	43,651.33

Notes:

- The above disclosure is in accordance with Clause 41(V)(h) of the listing agreement.
- The Standalone Financial statements have been prepared in accordance with the accounting principles generally accepted in India including Companies (Accounting Standards) Rules, 2006.
- The Consolidated financial information in accordance with IFRS has been extracted from the audited financial statements of the respective periods. The consolidated financial statements for the year ended March 31, 2011, are prepared in accordance with International Financial Reporting Standards and its interpretations (IFRS) . These are the Company's first consolidated financial statements prepared in accordance with IFRS and accordingly, as permitted by the SEBI Circular dated April 5, 2010, the Company has chosen to present information for the corresponding previous period as per the Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006. Accordingly, the previous year's consolidated financial information is not comparable with that of the current period.

For and on behalf of the Board of Directors

Mumbai, May 10, 2011
Visit us at www.glenmarkpharma.com

Glenn Saldanha
Managing Director & CEO